Related Experiment Video

Updated: Jun 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left

Alan H Gradman1, Vasilios Papademetriou

  • 1Division of Cardiovascular Diseases, The Western Pennsylvania Hospital, Pittsburgh, PA15224-1722, USA. gradmanmd@aol.com

American Heart Journal
|May 20, 2009
PubMed

Insights

Heart failure (HF) affects millions, with rising prevalence and costs. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can improve outcomes for patients with HF, particularly those with hypertension.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) prevalence is increasing, impacting millions with high mortality rates.
  • Older adults (≥65 years) experience a higher incidence of HF, projecting increased personal and economic burdens.
  • Hypertension is a major comorbidity in over 75% of HF patients, highlighting the need for effective blood pressure management.

Purpose of the Study:

  • To review clinical data on the efficacy of renin-angiotensin-aldosterone system (RAAS) inhibitors in managing heart failure.
  • To discuss the role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in improving HF outcomes.

Main Methods:

  • Review of clinical trial data and scientific literature.
  • Analysis of pharmacological interventions targeting the RAAS pathway.

Main Results:

  • Blood pressure control in hypertensive HF patients reduces cardiovascular events and mortality.
  • RAAS blockade mitigates detrimental effects of chronic RAAS activation on HF progression.
  • ACEIs and ARBs, used alone or in combination, demonstrate benefits in HF patient outcomes.

Conclusions:

  • ACEIs and ARBs are crucial in managing heart failure, especially in patients with hypertension.
  • Targeting the RAAS pathway offers a significant therapeutic strategy for improving HF prognosis.
  • Combined use of ACEIs and ARBs may provide additive benefits for HF patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...